CERUS CORP Files SEC form 10-Q, Quarterly Report

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This discussion and analysis should be read in conjunction with our condensed consolidated financial statements and the accompanying notes included in this report and the audited consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2008. Operating results for the three and nine months ended September 30, 2009 are not necessarily indicative of results that may occur in future periods. This report contains forward-looking statements that involve risks and uncertainties. The forward-looking statements are contained principally in the sections entitled "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Risk Factors." These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, without limitation, statements about our ability to commercialize and achieve market acceptance of the INTERCEPT Blood Systems, the successful completion of our research, development and clinical programs, our ability to manage cost increases associated with pre-clinical and clinical development for the INTERCEPT Blood Systems, our ability to obtain and maintain regulatory approvals of the INTERCEPT Blood Systems, our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others and our estimates regarding the sufficiency of our cash resources. In some cases, you can identify forward-looking statements by terms such as "anticipate," "will," "believe," "estimate," "expect," "plan," and similar ex...
Click here to read the whole Article (external link)

CERUS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Material Modification to Rights of Securit

ITEM 3.03. MATERIAL MODIFICATION TO RIGHTS OF SECURITY HOLDERS. As set forth under Item 1.01 of this Current Report on Form 8-K, on October 28, 2009, the Company entered into an amendment to the Rights Agreement (the "Amendment"). The Amendment provides, among other things, for a decrease in the initial exercise price of the Rights under the Rights Agreement from $170.00 to $30.00 per one one-hundredth of a Preferred Share, and an extension of the final expiration date of the Rights from November 3, 2009 to October 27, 2019. Each one one-hundredth of a Preferred Share has designations and powers, preferences and rights, and the qualifications, limitations and restrictions designed to make it the economic equivalent of a Common Share. The Rights will continue to be evidenced by the stock certificates representing the Common Shares then outstanding, unless and until they are separated upon the occurrence of certain future events. The Amendment also provides for revisions to certain definitions in the Rights Agreement, including revisions to the definition of beneficial ownership under the Rights Agreement to include ownership of certain derivative securities, as well as other technical changes. The Rights have certain anti-takeover effects. The Rights will cause substantial dilution to a person or group that attempts to acquire the Company on terms not approved by the Board. The Rights should not interfere with any merger or other business combination approved by the Board since the Rights may be amended to permit such acquisition or redeemed by the Company at $0.001 per Right prior to the earlier of (i) a person or group of affiliated or associated persons acquiring beneficial ownership of 15% or more of the outstanding Common Shares or (iii) the final expiration date of the Rights. The Board may terminate the Rights Agreement at any time or redeem the Rights prior to the time a person (or a group of affiliated or associated persons) acquires beneficial ownership of 15% or more o...
Click here to read the whole Article (external link)

Cerus Earnings Call scheduled for 4:15 pm ET today

Call DetailsCerus Earnings Conference Call (Q3 2009)Thu, Oct 29, 2009, 4:15 pm EasternAbout Cerus (NasdaqGM:CERS)Cerus Corporation, a biomedical products company, engages in the development and commercialization of the INTERCEPT Blood System. The company’s INTERCEPT system is designed to inactivate blood-borne pathogens in donated blood components intended for transfusion. It markets the INTERCEPT system for platelets and plasma primarily in Europe, the Russian Federation, and the Middle East. The company is also developing INTERCEPT Blood System for red blood cells or red blood cell system, which is designed to inactivate blood-borne pathogens in donated red blood cells for transfusion. It has collaboration agreements with Baxter International, Inc., BioOne Corporation, and Laboratorios Grifols S.A., as well as the United States Armed Forces. The company was founded in 1991 and is based in Concord, California.More Info:Quote |Chart |News |Profile |Reports |Research |SEC |Msgs |Insider |Financials | Analyst Ratings...
Click here to read the whole Article (external link)

Cerus Corporation Receives FDA Blood Products Advisory Committee Guidance for Proposed INTERCEPT Blood System Phase III Trial Design

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (NASDAQ:CERS - News) announced today that the FDA's Blood Products Advisory Committee (BPAC) rendered a positive opinion on the proposed hemostatic efficacy and safety endpoints for a potential U.S. Phase III clinical trial of the INTERCEPT Blood System for platelets. The Committee disagreed with the safety margins for the trial proposed by Cerus, and recommended that the trial design include more stringent safety margins for comparing INTERCEPT-treated platelets and conventional platelets. In addition, the Committee rendered a positive opinion on a proposed pathway forward in which successful completion of the proposed Phase III trial would be followed by a post-marketing randomized control study and concurrent staged roll-out of the product. "The Committee's guidance supports further development of INTERCEPT in the United States," said Claes Glassell, president and chief executive officer of Cerus. "We now need to conduct further discussions with the FDA to agree upon a final protocol. The more stringent safety margins recommended by the Committee may require a clinical trial with a larger number of patients than had been proposed. We expect that it will take at least 12 months to complete the clinical trial preparations and partnering arrangements necessary for commencement of the potential trial.”The proposed Phase III clinical trial is desi...
Click here to read the whole Article (external link)

Cerus Corporation Stock Trading Halted; FDA Blood Products Advisory Committee to Review and Discuss Proposed Phase III Clinical Trial Design for the INTERCEPT Blood System

Copyright © 2009 Yahoo! All rights reserved. Privacy Policy - Terms of Service - Copyright Policy - Report Problems Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quote data delayed 15 minutes for Nasdaq, NYSE and Amex. Real-Time continuous streaming quotes are available through our premium service. You may turn streaming quotes on or off. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Yahoo! is not an investment adviser and does not provide, endorse or review any information or data contained herein....
Click here to read the whole Article (external link)

CERUS CORP Financials

Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback Quotes delayed, except where indicated otherwise.Delay times are 15 mins for NASDAQ, 20 mins for NYSE and Amex. See also delay times for other exchanges.Fundamental company data provided by Capital IQ. Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quotes are delayed at least 15 minutes. Real-...
Click here to read the whole Article (external link)

CERUS CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits

Show all filings for CERUS CORP | Request a Trial to NEW EDGAR Online Pro Form 8-K for CERUS CORP 17-Nov-2009Other Events, Financial Statements and Exhibits Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not...
Click here to read the whole Article (external link)

Playboy, Helicos: Early Volume Plays

Stock quotes in this article: PSUN , PLA , HLCS , ...
Click here to read the whole Article (external link)